Platinum Investment Management LTD Trimmed Acceleron Pharma (XLRN) Stake as Stock Declined; Align Technology Com (ALGN) Holder Goodman Financial Has Trimmed Its Stake

February 15, 2018 - By Vivian Park

Kerr Neilson decreased its stake in Acceleron Pharma Inc (XLRN) by 15.22% based on its latest 2017Q3 regulatory filing with the SEC. Platinum Investment Management Ltd sold 10,500 shares as the company’s stock declined 4.63% while stock markets rallied. The hedge fund run by Kerr Neilson held 58,500 shares of the biological products (no diagnostic substances) company at the end of 2017Q3, valued at $2.18 million, down from 69,000 at the end of the previous reported quarter. Platinum Investment Management Ltd who had been investing in Acceleron Pharma Inc for a number of months, seems to be less bullish one the $1.89 billion market cap company. The stock increased 0.55% or $0.23 during the last trading session, reaching $41.82. About 27,181 shares traded. Acceleron Pharma Inc. (NASDAQ:XLRN) has declined 22.43% since February 15, 2017 and is downtrending. It has underperformed by 39.13% the S&P500.

Goodman Financial Corp decreased its stake in Align Technology Inc Com (ALGN) by 11.63% based on its latest 2017Q3 regulatory filing with the SEC. Goodman Financial Corp sold 7,984 shares as the company’s stock rose 36.03% with the market. The institutional investor held 60,640 shares of the health care company at the end of 2017Q3, valued at $11.30M, down from 68,624 at the end of the previous reported quarter. Goodman Financial Corp who had been investing in Align Technology Inc Com for a number of months, seems to be less bullish one the $19.78 billion market cap company. The stock increased 0.14% or $0.35 during the last trading session, reaching $246.69. About 602,541 shares traded. Align Technology, Inc. (NASDAQ:ALGN) has risen 82.22% since February 15, 2017 and is uptrending. It has outperformed by 65.52% the S&P500.

Investors sentiment decreased to 0.93 in 2017 Q3. Its down 0.46, from 1.39 in 2017Q2. It dived, as 36 investors sold ALGN shares while 194 reduced holdings. 77 funds opened positions while 137 raised stakes. 62.92 million shares or 1.48% more from 62.01 million shares in 2017Q2 were reported. Coldstream Cap Mngmt accumulated 1,305 shares. 978 are held by Assetmark. Alps Inc reported 0% stake. Engineers Gate Manager Limited Partnership stated it has 0.09% in Align Technology, Inc. (NASDAQ:ALGN). 8 were reported by Plante Moran Fincl Advsr Ltd. Stifel Financial Corp has invested 0.04% in Align Technology, Inc. (NASDAQ:ALGN). Guggenheim Capital Limited Liability owns 489,408 shares. Clarivest Asset Management Ltd Liability Co reported 9 shares. Dubuque Retail Bank has invested 0.02% in Align Technology, Inc. (NASDAQ:ALGN). First Quadrant Limited Partnership Ca has invested 0.07% in Align Technology, Inc. (NASDAQ:ALGN). Morgan Stanley holds 0.03% or 526,427 shares. The Alabama-based Regions Finance has invested 0.01% in Align Technology, Inc. (NASDAQ:ALGN). Champlain Inv Ptnrs Ltd Company has 0.98% invested in Align Technology, Inc. (NASDAQ:ALGN). 23 are owned by Pittenger Anderson Incorporated. Tiedemann Wealth Mngmt Ltd Llc stated it has 0.08% in Align Technology, Inc. (NASDAQ:ALGN).

Goodman Financial Corp, which manages about $291.99 million and $204.60 million US Long portfolio, upped its stake in Kroger Co Com (NYSE:KR) by 26,756 shares to 189,954 shares, valued at $3.81 million in 2017Q3, according to the filing. It also increased its holding in Safeguard Scientifics Inc Com New (NYSE:SFE) by 27,340 shares in the quarter, for a total of 330,556 shares, and has risen its stake in Kimco Rlty Corp Com (NYSE:KIM).

Since February 2, 2018, it had 0 buys, and 1 insider sale for $11.91 million activity.

Among 13 analysts covering Align Technology (NASDAQ:ALGN), 11 have Buy rating, 0 Sell and 2 Hold. Therefore 85% are positive. Align Technology had 53 analyst reports since July 27, 2015 according to SRatingsIntel. Leerink Swann maintained the stock with “Buy” rating in Friday, October 27 report. The firm has “Neutral” rating given on Monday, October 3 by Robert W. Baird. Leerink Swann maintained Align Technology, Inc. (NASDAQ:ALGN) on Friday, July 28 with “Outperform” rating. The firm has “Buy” rating given on Tuesday, January 30 by Stifel Nicolaus. As per Friday, October 27, the company rating was maintained by Robert W. Baird. Stifel Nicolaus maintained it with “Buy” rating and $80 target in Friday, October 23 report. The stock of Align Technology, Inc. (NASDAQ:ALGN) earned “Buy” rating by Stifel Nicolaus on Monday, September 11. Bank of America upgraded it to “Buy” rating and $19300 target in Friday, July 28 report. The stock of Align Technology, Inc. (NASDAQ:ALGN) has “Buy” rating given on Thursday, January 4 by Credit Suisse. On Wednesday, November 18 the stock rating was initiated by Piper Jaffray with “Overweight”.

Analysts await Acceleron Pharma Inc. (NASDAQ:XLRN) to report earnings on March, 7. They expect $-0.60 EPS, down 17.65% or $0.09 from last year’s $-0.51 per share. After $-0.65 actual EPS reported by Acceleron Pharma Inc. for the previous quarter, Wall Street now forecasts -7.69% EPS growth.

Among 16 analysts covering Acceleron Pharma (NASDAQ:XLRN), 11 have Buy rating, 1 Sell and 4 Hold. Therefore 69% are positive. Acceleron Pharma had 35 analyst reports since August 13, 2015 according to SRatingsIntel. The stock of Acceleron Pharma Inc. (NASDAQ:XLRN) has “Overweight” rating given on Wednesday, September 20 by Barclays Capital. The rating was maintained by FBR Capital with “Buy” on Tuesday, June 13. The stock has “Overweight” rating by Barclays Capital on Monday, June 13. Barclays Capital initiated Acceleron Pharma Inc. (NASDAQ:XLRN) on Wednesday, April 27 with “Overweight” rating. Credit Suisse downgraded the stock to “Hold” rating in Thursday, September 21 report. As per Tuesday, August 1, the company rating was maintained by Oppenheimer. Credit Suisse maintained Acceleron Pharma Inc. (NASDAQ:XLRN) on Tuesday, November 14 with “Outperform” rating. FBR Capital maintained the stock with “Buy” rating in Friday, June 23 report. The rating was maintained by FBR Capital on Friday, January 15 with “Outperform”. Credit Suisse initiated the stock with “Outperform” rating in Thursday, January 21 report.

Since September 12, 2017, it had 1 insider purchase, and 12 sales for $19.61 million activity. Kumar Ravindra had sold 5,113 shares worth $196,418. MCLAUGHLIN KEVIN F sold $814,848 worth of stock or 19,000 shares. 2,266 shares valued at $96,134 were sold by Rovaldi Christopher on Tuesday, January 2. $183,806 worth of Acceleron Pharma Inc. (NASDAQ:XLRN) was sold by Quisel John D on Tuesday, January 2. 745,592 shares valued at $27.59M were bought by CELGENE CORP /DE/ on Monday, September 25. George Jean also sold $3.76M worth of Acceleron Pharma Inc. (NASDAQ:XLRN) on Friday, December 15.

Investors sentiment increased to 1.81 in Q3 2017. Its up 0.37, from 1.44 in 2017Q2. It is positive, as 12 investors sold XLRN shares while 30 reduced holdings. 30 funds opened positions while 46 raised stakes. 37.73 million shares or 12.48% more from 33.54 million shares in 2017Q2 were reported. Birchview Capital LP stated it has 0.48% in Acceleron Pharma Inc. (NASDAQ:XLRN). Artisan Partners Limited Partnership owns 319,871 shares for 0.02% of their portfolio. Loring Wolcott & Coolidge Fiduciary Advisors Ltd Liability Partnership Ma owns 337 shares. Pnc Financial Svcs Group Inc Incorporated holds 8,080 shares or 0% of its portfolio. Dekabank Deutsche Girozentrale invested in 18,900 shares. Credit Suisse Ag, Switzerland-based fund reported 89,972 shares. 350,000 are owned by Ghost Tree Cap Lc. Swiss National Bank reported 62,300 shares. Parametric Assoc Limited Liability Company owns 27,672 shares or 0% of their US portfolio. Barclays Public Ltd Co, United Kingdom-based fund reported 7,944 shares. Geode Mngmt Lc has 322,834 shares. Sg Americas Ltd invested in 0% or 12,239 shares. Congress Asset Management Ma reported 28,289 shares stake. Iguana Limited Liability Corp accumulated 70,000 shares. Ray Gerald L And Assocs Limited stated it has 8,600 shares or 0.04% of all its holdings.

Platinum Investment Management Ltd, which manages about $22.00B and $3.96 billion US Long portfolio, upped its stake in Dermira Inc (NASDAQ:DERM) by 34,700 shares to 92,400 shares, valued at $2.49M in 2017Q3, according to the filing. It also increased its holding in Nanostring Technologies Inc (NASDAQ:NSTG) by 29,000 shares in the quarter, for a total of 121,000 shares, and has risen its stake in Skyworks Solutions Inc (NASDAQ:SWKS).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: